Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

August 31, 2013

Conditions
Hepatitis B, Chronic
Interventions
DRUG

PEG-Tα1

1.6 mg/ml, once a week, taken subcutaneously

DRUG

Placebo to match PEG-Tα1

1ml, once a week, taken subcutaneously

DRUG

Adefovir

10 mg, once daily, taken orally for 48 weeks

Trial Locations (12)

Unknown

302 Military Hoapital of China, Beijing

Hainan General Hospital, Haikou

The Third Hospital of Hebei Medical University, Shijiazhuang

The Second Xiangya Hospital of Central South University, Changsha

81 Military Hospital of China, Nanjing

Jiangsu Province Hospital, Nanjing

The Second Hospital of Nanjing, Nanjing

The First Hospital of Jilin University, Changchun

The Sixth People's Hospital of Shenyang, Shenyang

The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi’an

West China Hospital Sichuan University, Chengdu

All Listed Sponsors
collaborator

Nanjing Medical University

OTHER

lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY